Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial

NCT04907682 is registered in ClinicalTrials.gov with Bernhard Nocht Institute for Tropical Medicine as lead sponsor.

NCT NCT04907682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04907682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial
Lead sponsor
Bernhard Nocht Institute for Tropical Medicine
Phase
Phase 2
Overall status
Completed
Start date
July 30, 2021
Completion date
November 17, 2022
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lassa fever